| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Levofloxacin [(-)-Ofloxacin, Levaquin, Tavanic, Fluoroquinolone, Iquix, Quixin], a synthetic fluoroquinolone and the levo isomer of ofloxacin, is a broad-spectrum antibacterial drug approved for treating UTIs, RTIs etc. It inhibits DNA replication by blocking bacterial DNA gyrase's ability to supercoil. Levofloxacin is used to treat infections caused by bacteria in the stomach, urinary tract, respiratory system, and abdomen. With the exception of anaerobes, levofloxacin is only moderately active against the majority of aerobic Gram-positive and Gram-negative organisms.
| Targets |
Quinolone; TOPO IV
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Animal Protocol |
Matured male Albino mice
10.7 mg/kg Intraperitoneal injection; 10.7 mg/kg, once daily for 10 days or 3 weeks. |
|
| References |
| Molecular Formula |
C18H20FN3O4
|
|
|---|---|---|
| Molecular Weight |
361.37
|
|
| Exact Mass |
361.14
|
|
| Elemental Analysis |
C, 59.83; H, 5.58; F, 5.26; N, 11.63; O, 17.71
|
|
| CAS # |
100986-85-4
|
|
| Related CAS # |
138199-71-0； 177325-13-2；872606-49-0
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
|
|
| InChi Key |
GSDSWSVVBLHKDQ-JTQLQIEISA-N
|
|
| InChi Code |
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
|
|
| Chemical Name |
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (27.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7672 mL | 13.8362 mL | 27.6725 mL | |
| 5 mM | 0.5534 mL | 2.7672 mL | 5.5345 mL | |
| 10 mM | 0.2767 mL | 1.3836 mL | 2.7672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03850379 | Active Recruiting |
Drug: Levofloxacin Drug: Ciprofloxacin |
Prophylaxis Stem Cell Transplant Complications |
Henry Ford Health System | March 14, 2018 | Phase 2 |
| NCT03236961 | Active Recruiting |
Drug: Ertapenem Drug: Moxifloxacin |
Acute Appendicitis | Turku University Hospital | April 3, 2017 | Not Applicable |
| NCT04062201 | Active Recruiting |
Drug: Levofloxacin Oral Tablet Drug: Linezolid Oral Tablet |
Tuberculosis Pre-XDR-TB |
Wits Health Consortium (Pty) Ltd |
August 22, 2019 | Phase 3 |
| NCT01022567 | Active Recruiting |
Procedure: Appendicectomy Drug: Ertapenem |
Acute Appendicitis | Turku University Hospital | November 2009 | Not Applicable |
| NCT05799326 | Recruiting | Drug: Levofloxacin simulant Drug: Levofloxacin |
Acute Ischemic Stroke | Yi Yang | June 30, 2023 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA